(Q46728070)

24 December 2017

title

Beneficial effects of rosiglitazone on novel cardiovascular risk factors in patients with Type 2 diabetes mellitus (English)

1 reference

24 December 2017

0 references

1 reference

1 reference

N P E Kadoglou

1

1 reference

24 December 2017

F Iliadis

2

1 reference

24 December 2017

N Angelopoulou

3

1 reference

24 December 2017

D Perrea

4

1 reference

24 December 2017

C D Liapis

5

1 reference

24 December 2017

M Alevizos

6

1 reference

24 December 2017

publication date

1 March 2008

1 reference

24 December 2017

published in

Diabetic Medicine

1 reference

24 December 2017

volume

25

1 reference

24 December 2017

issue

3

1 reference

24 December 2017

page(s)

333-340

1 reference

24 December 2017

Diabetes and cardiovascular disease: a statement for healthcare professionals from the American Heart Association

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2007.02375.X

Physical activity in relation to cardiovascular disease and total mortality among men with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2007.02375.X

The association between diabetic complications and exercise capacity in NIDDM patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2007.02375.X

Low cardiorespiratory fitness and physical inactivity as predictors of mortality in men with type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2007.02375.X

Meta-analysis of the effect of structured exercise training on cardiorespiratory fitness in Type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2007.02375.X

Determinants of exercise capacity in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2007.02375.X

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2007.02375.X

Nonhypoglycemic effects of thiazolidinediones

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2007.02375.X

Rosiglitazone improves exercise capacity in individuals with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2007.02375.X

Review: Peroxisome proliferator-activated receptor gamma and adipose tissue--understanding obesity-related changes in regulation of lipid and glucose metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2007.02375.X

Adiponectin and Metabolic Syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2007.02375.X

Matrix metalloproteinases: contribution to pathogenesis, diagnosis, surveillance and treatment of abdominal aortic aneurysms.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2007.02375.X

Relations of plasma total TIMP-1 levels to cardiovascular risk factors and echocardiographic measures: the Framingham heart study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2007.02375.X

Antidiabetic PPAR gamma-activator rosiglitazone reduces MMP-9 serum levels in type 2 diabetic patients with coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2007.02375.X

Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2007.02375.X

Insulin resistance: From predisposing factor to therapeutic target in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2007.02375.X

Daily walking reduces visceral adipose tissue areas and improves insulin resistance in Japanese obese subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2007.02375.X

Exercise capacity and body composition as predictors of mortality among men with diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2007.02375.X

Peak oxygen intake and cardiac mortality in women referred for cardiac rehabilitation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2007.02375.X

Relationship of changes in maximal and submaximal aerobic fitness to changes in cardiovascular disease and non-insulin-dependent diabetes mellitus risk factors with endurance training: the HERITAGE Family Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2007.02375.X

Reciprocal relationships between abnormal metabolic parameters and endothelial dysfunction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2007.02375.X

In type 2 diabetes, rosiglitazone therapy for insulin resistance ameliorates endothelial dysfunction independent of glucose control

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2007.02375.X

Vascular effects of improving metabolic control with metformin or rosiglitazone in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2007.02375.X

Effect of rosiglitazone on glucose and non-esterified fatty acid metabolism in Type II diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2007.02375.X

The effects of rosiglitazone, a peroxisome proliferator-activated receptor-gamma agonist, on markers of endothelial cell activation, C-reactive protein, and fibrinogen levels in non-diabetic coronary artery disease patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2007.02375.X

Thiazolidinediones reduce endothelial expression of receptors for advanced glycation end products

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2007.02375.X

Adiponectin stimulates production of nitric oxide in vascular endothelial cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2007.02375.X

Impact of rosiglitazone on beta-cell function, insulin resistance, and adiponectin concentrations: results from a double-blind oral combination study with glimepiride

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2007.02375.X

The effects of rosiglitazone and metformin on the plasma concentrations of resistin in patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2007.02375.X

Left ventricular diastolic dysfunction in diabetic patients: pathophysiology and therapeutic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2007.02375.X

Pioglitazone improves left ventricular diastolic function in patients with essential hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2007.02375.X

Impact of adjunctive thiazolidinedione therapy on blood lipid levels and glycemic control in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2007.02375.X

Rosiglitazone improves insulin sensitivity and lowers blood pressure in hypertensive patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2007.02375.X

Effects of pioglitazone versus glipizide on body fat distribution, body water content, and hemodynamics in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2007.02375.X

Role of the adipocyte, free fatty acids, and ectopic fat in pathogenesis of type 2 diabetes mellitus: peroxisomal proliferator-activated receptor agonists provide a rational therapeutic approach

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2007.02375.X

Matrix metalloproteinase-9 (MMP-9), MMP-2, and serum elastase activity are associated with systolic hypertension and arterial stiffness

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2007.02375.X

Matrix metalloproteinases and diabetic vascular complications.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2007.02375.X

Peroxisome proliferator-activated receptor gamma activators inhibit gene expression and migration in human vascular smooth muscle cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2007.02375.X

Inhibition of MMP-9 expression by PPARgamma activators in human bronchial epithelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2007.02375.X

Pioglitazone inhibits cell growth and reduces matrix production in human kidney fibroblasts.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2007.02375.X

Peroxisome proliferator-activated receptor and retinoid X receptor ligands inhibit monocyte chemotactic protein-1-directed migration of monocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2007.02375.X

Effect of Rosiglitazone on Endothelial Function and Inflammatory Markers in Patients With the Metabolic Syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2007.02375.X

10.1111/J.1464-5491.2007.02375.X

21 January 2018

Identifiers

DOI

1 reference

24 December 2017

1 reference

24 December 2017